港股异动 | 歌礼制药-B(01672)早盘涨超12% 去年公司管线做出重大战略调整减肥药物效果优异

智通财经网2025-04-15

歌礼制药-B(01672)早盘涨超12%，截至发稿，涨12.31%，报6.48港元，成交额1956.19万港元。光大证券发布研报称，2024年，歌礼制药对于公司管线做出重大战略调整。公司决定终止病毒性疾病治疗管线，包括慢乙肝、HIV、RSV在研产品，以及终止MASH治疗产品ASC41的临床推进。同时公司新增肥胖及代谢性疾病临床管线，分别是GLP受体激动剂ASC30与THR-β激动剂ASC47，截至...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2527486073?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-15 11:19","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2527486073","market":"fut","top_or_hot":-1,"title":"港股异动 | 歌礼制药-B(01672)早盘涨超12% 去年公司管线做出重大战略调整 减肥药物效果优异","media":"智通财经网","content":"<div>\n<p>歌礼制药-B(01672)早盘涨超12%，截至发稿，涨12.31%，报6.48港元，成交额1956.19万港元。光大证券发布研报称，2024年，歌礼制药对于公司管线做出重大战略调整。公司决定终止病毒性疾病治疗管线，包括慢乙肝、HIV、RSV在研产品，以及终止MASH治疗产品ASC41的临床推进。同时公司新增肥胖及代谢性疾病临床管线，分别是GLP受体激动剂ASC30与THR-β激动剂ASC47，截至...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-15/doc-inetfhry8003767.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 歌礼制药-B(01672)早盘涨超12% 去年公司管线做出重大战略调整 减肥药物效果优异</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 歌礼制药-B(01672)早盘涨超12% 去年公司管线做出重大战略调整 减肥药物效果优异\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-15 11:19 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-15/doc-inetfhry8003767.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>歌礼制药-B(01672)早盘涨超12%，截至发稿，涨12.31%，报6.48港元，成交额1956.19万港元。光大证券发布研报称，2024年，歌礼制药对于公司管线做出重大战略调整。公司决定终止病毒性疾病治疗管线，包括慢乙肝、HIV、RSV在研产品，以及终止MASH治疗产品ASC41的临床推进。同时公司新增肥胖及代谢性疾病临床管线，分别是GLP受体激动剂ASC30与THR-β激动剂ASC47，截至...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-15/doc-inetfhry8003767.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-15/doc-inetfhry8003767.shtml","article_id":"2527486073","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527486073","pubTimestamp":1744687140,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"歌礼制药-B早盘涨超12%，截至发稿，涨12.31%，报6.48港元，成交额1956.19万港元。光大证券发布研报称，2024年，歌礼制药对于公司管线做出重大战略调整。同时公司新增肥胖及代谢性疾病临床管线，分别是GLP受体激动剂ASC30与THR-β激动剂ASC47，截至24年末，二者在海外均已推进至临床I期。公司口服与皮下注射减肥产品初步展现出优异的减重效果与长半衰期，在同类竞品中具备独特优势。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","01672":"歌礼制药-B","01477":"欧康维视生物-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Changes in Hong Kong stocks Ascletis Pharmaceuticals-B (01672) rose more than 12% in early trading. Last year, the company made major strategic adjustments to its pipeline and weight loss drugs were effective","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1,"01477":1},"content_text":"歌礼制药-B(01672)早盘涨超12%，截至发稿，涨12.31%，报6.48港元，成交额1956.19万港元。光大证券发布研报称，2024年，歌礼制药对于公司管线做出重大战略调整。公司决定终止病毒性疾病治疗管线，包括慢乙肝、HIV、RSV在研产品，以及终止MASH治疗产品ASC41的临床推进。同时公司新增肥胖及代谢性疾病临床管线，分别是GLP受体激动剂ASC30与THR-β激动剂ASC47，截至24年末，二者在海外均已推进至临床I期。24年公司研发开支同比增长39.5%至3.02亿元，其中代谢性疾病研发开支近1亿元，痤疮治疗产品因进入临床3期产生研发开支近8千万元。公司账面尚有现金及现金等价物、定期存款、可转让存单等合计约19.8亿元，预计可以支撑公司研发及运营至2029年。该行续指，24年公司开展多个肥胖相关I期临床，包括：1)ASC30每日口服治疗肥胖患者，治疗28天后两个队列患者体重相对基线平均下降4.2%和6.2%(经安慰剂调整)；2)ASC30每月一次或更低频率皮下注射治疗肥胖患者，此前在动物模型内其半衰期长达40天；3)ASC47每月一次或更低频率皮下注射治疗肥胖患者，I b期试验中展现长半衰期(健康受试者26天，肥胖患者40天)，单次皮下注射90mg后，肥胖患者第 50天峰值减重达 1.7%，且未出现肌肉流失。公司口服与皮下注射减肥产品初步展现出优异的减重效果与长半衰期，在同类竞品中具备独特优势。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2527486073","isCrawlerRequest":true}

港股异动 | 歌礼制药-B(01672)早盘涨超12% 去年公司管线做出重大战略调整 减肥药物效果优异

精彩评论

港股异动 | 歌礼制药-B(01672)早盘涨超12% 去年公司管线做出重大战略调整减肥药物效果优异